Toufic Kachaamy, MD, discusses an upcoming course that teaches the multidisciplinary approach for clinicians who have a hand in treating gastrointestinal cancers.
Toufic Kachaamy, MD, Enterprise program leader, Interventional Programs and Medical Director of Gastroenterology at Cancer Treatment Centers of America Phoenix, discusses an upcoming course for clinicians who have a hand in treating gastrointestinal (GI) cancers.
The continuing medical education course titled "Interventional Gastroenterology and Multidisciplinary Gastrointestinal Cancer Care" will be held on Saturday, April 23, 2022, in Scottsdale, Arizona.
Kachaamy explains that this course was developed to fill an education gap for clinicians who treat GI cancers. Considering this, the intended audience includes medical oncologists, radiation oncologists, surgical oncologists and surgeons, gastroenterologists, advance practice providers and nurses, palliative care providers, and interventionalists.
0:07 | We realized a gap in multidisciplinary care, especially as it relates to the expanding capabilities of interventional gastroenterology. There is nothing out there that serves to bridge that gap to educate the multidisciplinary oncology team on the capabilities of gastroenterology, especially therapeutic endoscopy and also to educate community therapeutic ambassadors as to what the oncologist, radiation oncologists, and surgical oncologists need from them.
0:44 | So, realizing that gap, we decided to build a CME course with that focus on the innovation in gastroenterology and the needs of the multidisciplinary team from the interventional GI world. And our inaugural CME will be on April 23 in Phoenix. We're very excited about it. There's been a lot of enthusiasm about it. And we're hoping to be able to bridge that gap in knowledge and skills.
Learn more about the CME course offered by CTCA >>
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More